Renal Denervation

  • Dani Id
  • Benjamin Kaltenbach
  • Jennifer Franke
  • Horst Sievert


Renal sympathetic denervation is a novel and promising therapy option for patients with treatment-resistant primary arterial hypertension. By ablating renal sympathetic nerves in the wall of the renal artery, blood pressure decreases significantly without affecting renal function. This intervention is technically straightforward, and possible relevant procedure-specific complications are rare.

Extended indications are under investigation including milder forms of hypertension or heart failure. Future studies should reveal the full potential of this novel technique of blood pressure control possibly introducing renal sympathetic denervation into the clinical routine.

The kidney is an important player in blood pressure regulation. While the principles of blood pres­sure regulation by renin-angiotensin-aldosterone system, RAAS, have been to a large extent explored, the knowledge of blood pressure regulation via renal sympathetic innervation remains rudimentary. Nevertheless, it appears that continuously elevated renal sympathetic drive may be an important factor in the pathophysiology of arterial hypertension. In majority of these cases, antihypertensive drug regimes fail to lower blood pressure to target levels. Recently, reducing elevated (renal) sympathetic nerve activity by disrupting the interactions between the kidney and the sympathetic nervous system through catheter-based renal denervation has appeared as a potentially effective treatment option. The sympathetic renal nerves lie in the adventitia of the renal arteries approximately 3–4 mm abluminal, which makes them accessible for disruption by radiofrequency energy without any relevant collateral damage to the surrounding tissues. The endovascular concept of denervation of the renal sympathetic nerves includes the use of a radiofrequency catheter with a steerable electrode tip which is connected to a radiofrequency generator. Employing this novel endovascular technique, the early results in a limited number of patients showed a markedly improved blood pressure control in about 85% of treated patients [1].


Renal Artery Office Blood Pressure Renal Denervation Radiofrequency Energy Renal Nerve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Esler MD et al (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756):1903–1909PubMedCrossRefGoogle Scholar
  2. 2.
    Kearney PM et al (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365(9455):217–223PubMedGoogle Scholar
  3. 3.
    Lewington S et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903–1913PubMedCrossRefGoogle Scholar
  4. 4.
    Lubanski MS, McCullough PA (2009) Kidney’s role in hypertension. Minerva Cardioangiol 57(6):743–759PubMedGoogle Scholar
  5. 5.
    Mark AL (1996) The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens Suppl 14(5):S159–S165PubMedGoogle Scholar
  6. 6.
    DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77(1):75–197PubMedGoogle Scholar
  7. 7.
    Calhoun DA et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51(6):1403–1419PubMedCrossRefGoogle Scholar
  8. 8.
    Symplicity HTN-1 Investigators (2011) Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5):911–917CrossRefGoogle Scholar
  9. 9.
    Mahfoud F et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18):1940–1946PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Dani Id
    • 1
  • Benjamin Kaltenbach
    • 1
  • Jennifer Franke
    • 1
  • Horst Sievert
    • 1
  1. 1.CardioVascular Center FrankfurtFrankfurtGermany

Personalised recommendations